Form 4: Axsome Therapeutics Director Roger Jeffs Acquires Stock Options
SEC Filing Form 4
Director Roger Jeffs of Axsome Therapeutics acquired 5,799 stock options on June 7, 2024, exercisable starting June 7, 2025.
Summary
- Roger Jeffs, a director of Axsome Therapeutics, acquired 5,799 stock options on June 7, 2024.
- The options have an exercise price of $73.90.
- The options vest in full on June 7, 2025, and expire on June 7, 2034.
- Following the transaction, Jeffs directly owns 5,799 derivative securities.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, so the sentiment is neutral.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company directors and officers.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.
Key Dates
| Date | Description |
|---|---|
| 06/07/2024 | Date of transaction: Roger Jeffs acquired stock options. |
| 06/07/2025 | Date the options vest in full. |
| 06/07/2034 | Expiration date of the options. |
| 06/11/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.